Record Information |
---|
Version | 2.0 |
---|
Created at | 2022-05-30 16:51:18 UTC |
---|
Updated at | 2022-05-30 16:51:18 UTC |
---|
NP-MRD ID | NP0137397 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Bleomycin sulfate |
---|
Description | Bleomycin, also known as bleomycin sulfate or BLM, belongs to the class of organic compounds known as hybrid glycopeptides. Hybrid glycopeptides are compounds containing a carbohydrate component linked to a hybrid peptide component. Thus, bleomycin is considered to be a non-ribosomal peptide/polyketide hybrid lipid molecule. Bleomycin is a drug which is used for palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. Bleomycin is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Bleomycin is formally rated as a possible carcinogen (by IARC 2B) and is also a potentially toxic compound. Umezawa published his discovery in 1966. Any previous treatment with bleomycin should therefore always be disclosed to the anaesthetist prior to undergoing a procedure requiring general anaesthesia. Bleomycin sulfate is found in Streptomyces verticillus. Bleomycin sulfate was first documented in 1999 (PMID: 11749501). The most serious complication of bleomycin, occurring upon increasing dosage, is pulmonary fibrosis and impaired lung function. |
---|
Structure | C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1 |
---|
Synonyms | Value | Source |
---|
Bleocin | HMDB | Bleomicin | HMDB | Bleomycin a2 | HMDB | Bleomycin sulfate | HMDB | Bleomycin sulphate | HMDB | BLM | HMDB | Almirall brand OF bleomycin sulfate | HMDB | Bleo cell | HMDB | Bleo-cell | HMDB | BLEOcell | HMDB | Bellon brand OF bleomycin sulfate | HMDB | Bellon, bléomycine | HMDB | Blanoxan | HMDB | Blenoxane | HMDB | Bleolem | HMDB | Bleomicina | HMDB | Bleomycin a(2) | HMDB | Bleomycin b(2) | HMDB | Bleomycin b2 | HMDB | Bleomycins | HMDB | Bleomycinum mack | HMDB | Bléomycine bellon | HMDB | Bristol myers squibb brand OF bleomycin sulfate | HMDB | Bristol-myers squibb brand OF bleomycin sulfate | HMDB | Bull brand OF bleomycin sulfate | HMDB | Lemery brand OF bleomycin sulfate | HMDB | Lundbeck brand OF bleomycin sulfate | HMDB | Mack brand OF bleomycin sulfate | HMDB | Mack, bleomycinum | HMDB | Sulfate, bleomycin | HMDB | Cell pharm brand OF bleomycin sulfate | HMDB | Bleomycin | MeSH |
|
---|
Chemical Formula | C55H84N17O21S3 |
---|
Average Mass | 1415.5520 Da |
---|
Monoisotopic Mass | 1414.51898 Da |
---|
IUPAC Name | (3-{[2-(2-{2-[(2S,3R)-2-[(2S,3S,4R)-4-[(2S,3R)-2-({6-amino-2-[(1S)-1-{[(2S)-2-amino-2-carbamoylethyl]amino}-2-carbamoylethyl]-5-methylpyrimidin-4-yl}formamido)-3-[(3-{[4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]-3-(1H-imidazol-5-yl)propanamido]-3-hydroxy-2-methylpentanamido]-3-hydroxybutanamido]ethyl}-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]formamido}propyl)dimethylsulfanium |
---|
Traditional Name | bleomycin |
---|
CAS Registry Number | Not Available |
---|
SMILES | C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C |
---|
InChI Identifier | InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1 |
---|
InChI Key | OYVAGSVQBOHSSS-WXFSZRTFSA-O |
---|
Experimental Spectra |
---|
|
| Not Available | Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as hybrid glycopeptides. Hybrid glycopeptides are compounds containing a carbohydrate component linked to a hybrid peptide component. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Peptidomimetics |
---|
Sub Class | Hybrid peptides |
---|
Direct Parent | Hybrid glycopeptides |
---|
Alternative Parents | |
---|
Substituents | - Hybrid glycopeptide
- Histidine or derivatives
- Fatty acyl glycoside of mono- or disaccharide
- Fatty acyl glycoside
- N-acyl-alpha amino acid or derivatives
- Gamma amino acid or derivatives
- Alpha-amino acid amide
- Beta amino acid or derivatives
- O-glycosyl compound
- Glycosyl compound
- Disaccharide
- N-substituted-alpha-amino acid
- Alpha-amino acid or derivatives
- Pyrimidine-6-carboxylic acid or derivatives
- 2-heteroaryl carboxamide
- Thiazolecarboxamide
- Thiazolecarboxylic acid or derivatives
- Aralkylamine
- 2,4-disubstituted 1,3-thiazole
- Aminopyrimidine
- Fatty amide
- Fatty acyl
- N-acyl-amine
- Imidolactam
- Oxane
- Pyrimidine
- Azole
- Carbamic acid ester
- Heteroaromatic compound
- Thiazole
- Imidazole
- Secondary alcohol
- Carboxamide group
- Carbonic acid derivative
- Amino acid or derivatives
- Secondary carboxylic acid amide
- Primary carboxylic acid amide
- Organoheterocyclic compound
- Secondary aliphatic amine
- Oxacycle
- Acetal
- Carboxylic acid derivative
- Azacycle
- Secondary amine
- Organic nitrogen compound
- Organic oxygen compound
- Primary aliphatic amine
- Organonitrogen compound
- Organooxygen compound
- Carbonyl group
- Organosulfur compound
- Primary alcohol
- Primary amine
- Amine
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Alcohol
- Organic cation
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|